A study in the journal American Journal of Health-System Pharmacy ranked the top 25 drugs by US expenditure in 2023 based on list price, newly approved drugs and utilization, with semaglutide, adalimumab and apixaban taking the top three spots. Over $38 billion was spent on semaglutide, a 100% increase over 2022.

Full Story: Becker’s Hospital Review